Prothena to Participate in JMP Securities Life Sciences Conference on June 16
Dublin-based Prothena Corporation plc (NASDAQ:PRTA) announced participation in a fireside chat at the JMP Securities Life Sciences Conference on June 16, 2021, at 3:00 PM ET. The chat will be accessible via a live webcast on the company’s investor relations website, with a replay available for 90 days post-event. Prothena focuses on developing therapies targeting protein dysregulation related to rare peripheral amyloid and neurodegenerative diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s, and Parkinson’s disease.
- None.
- None.
DUBLIN, Ireland, June 10, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the JMP Securities Life Sciences Conference on Wednesday, June 16 at 3:00 PM ET
A live webcast of the fireside chat can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.
About Prothena
Prothena Corporation plc is a late-stage clinical company with a robust pipeline of novel investigational therapeutics, built on protein dysregulation expertise, with the potential to change the course of devastating rare peripheral amyloid and neurodegenerative diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.
Investors & Media
Jennifer Zibuda, Director, Investor Relations & Communications
650-837-8535, jennifer.zibuda@prothena.com
FAQ
When will Prothena participate in the JMP Securities Life Sciences Conference?
How can I access the live webcast of Prothena's fireside chat?
What diseases is Prothena focusing on with its investigational therapeutics?
What is the stock symbol for Prothena Corporation?
Will there be a replay of the fireside chat after the live event?
